The company has just two quarters’ of cash remaining, but has also achieved major milestones towards the development and commercialization of its implant that hopes to restore vision in patients with age-related macular degeneration.

Times may look bleak for medtech investment. Public markets are down and VC is shyer than ever about spending money. Medtech Insight spoke to Antoine Papiernik of Sofinnova Partners to learn more about the path forward.

As Omicron further destabilizes the medtech space, potentially mirroring the spring of 2020, some executives shared with Medtech Insight their views on what will hopefully be a bumper year for the sector.

Keeping the patient at the center is just as important in the development of high-risk innovations that serve unmet needs as it is for all other medtech solutions. That is the view of Pixium Vision CEO Khalid Ishaque, whose company is on the cusp of taking many dry-AMD sufferers out of blindness with artificial bionic vision technology. It recently performed the first successful human implantation and activation of its Prima implant.